Onderzoeker
Ine Moors
- Disciplines:Palliatieve zorg en zorg rond het levenseinde, Laboratoriumgeneeskunde, Andere translationele wetenschappen, Regeneratieve geneeskunde, Verpleegkunde, Andere klinische wetenschappen, Andere basiswetenschappen, Andere paramedische wetenschappen, Andere gezondheidswetenschappen, Andere medische en gezondheidswetenschappen
Affiliaties
- Vakgroep Inwendige ziekten (Departement)
Lid
Vanaf24 sep 2015 → 25 sep 2016
Publicaties
1 - 10 van 22
- Clinical impact of polymerase chain reaction-based Aspergillus and azole resistance detection in invasive aspergillosis : a prospective multicenter study(2023)
Auteurs: Albert Dunbar, Jochem B. Buil, Corne H. W. Klaassen, Paul E. Verweij, Karin van Dijk, Nick de Jonge, Jeroen J. W. M. Janssen, Walter J. F. M. van der Velden, Bart J. Biemond, Aldert Bart, et al.
Pagina's: 38 - 45 - Identification of the most important factors related to people with cancer starting a palliative care conversation : a survey study(2022)
Auteurs: Kim Beernaert, Martine De Laat, Christine Biebuyck, Karen Geboes, Ine Moors, Joachim Cohen
Pagina's: 1843 - 1851 - Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study) : a retrospective comparative cohort study(2021)
Auteurs: Alexander Schauwvlieghe, A. Dunbar, E. Storme, A. Vlak, R. Aerts, J. Maertens, B. Sciot, T. Van der Wel, G. Papageorgiou, Ine Moors, et al.
- Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with AML and high risk MDS(2021)
Auteurs: Jeroen Janssen, Bob Lowenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Peter von Dem Borne, Dimitri Breems, Rolf Brouwer, Yves Chalandon, Dries Deeren, et al.
- Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : the HOVON-SAKK-132 trial(2021)
Auteurs: Bob Lowenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, et al.
Pagina's: 1110 - 1121 - Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS(2020)
Auteurs: G. Stuessi, Y. Van Norden, P. A von dem Borne, J. Cloos, B. Gjertsen, J. J. J. W. Janssen, A. Jaspers, E. De Jongh, J. Maertens, L. Micheaux, et al.
Pagina's: 1751 - 1759 - TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment(2020)
Auteurs: Barbara Depreter, Karin Weening, Karl Vandepoele, Magnus Essand, Maria Themeli, Jacqueline Cloos, Diana Hanekamp, Ine Moors, INGE D'HONT, Barbara Denys, et al.
Pagina's: 1306 - 1316 - TARP as immunotherapeutic target in AML expressed in the LSC compartment(2019)Volume: 3
Auteurs: Barbara Depreter, Karin Weening, Karl Vandepoele, M Essand, M Themeli, J Cloos, D Hanekamp, Ine Moors, INGE D'HONT, Barbara Denys, et al.
Pagina's: 54 - 54 - Vaccination following stem cell transplantation in adults: initiatives to improve vaccination adherence and follow-up(2016)Volume: 51
Auteurs: J De Munter, M Quaghebeur, T Bauters, Ine Moors, Tessa Kerre
Pagina's: S524 - S524 - Proctological problems in relation to chemotherapy(2013)Volume: 144
Auteurs: BRUNO VANDUYFHUYS, INGRID BRUGGEMAN, KOEN GORLEER, Pieter Hindryckx, Daan De Maeseneer, Ine Moors, Stéphanie Laurent, Karen Geboes, Tessa Kerre, Simon Van Belle, et al.
Pagina's: S1071 - S1071